

# Juan E Grunwald

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5254814/publications.pdf>

Version: 2024-02-01

64  
papers

9,137  
citations

136740

32  
h-index

118652

62  
g-index

64  
all docs

64  
docs citations

64  
times ranked

5882  
citing authors

| #  | ARTICLE                                                                                                                                                                       | IF   | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1  | Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. <i>New England Journal of Medicine</i> , 2011, 364, 1897-1908.                                  | 13.9 | 2,355     |
| 2  | Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 1388-1398.                                       | 2.5  | 1,550     |
| 3  | Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 1751-1761.       | 2.5  | 541       |
| 4  | Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT. <i>Ophthalmology</i> , 2018, 125, 537-548.                                          | 2.5  | 485       |
| 5  | Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2014, 121, 150-161.                                | 2.5  | 483       |
| 6  | Reduced Foveolar Choroidal Blood Flow in Eyes with Increasing AMD Severity. , 2005, 46, 1033.                                                                                 |      | 269       |
| 7  | Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2013, 120, 122-129. | 2.5  | 268       |
| 8  | Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2014, 121, 656-666.                                              | 2.5  | 232       |
| 9  | Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2013, 120, 1860-1870.                    | 2.5  | 226       |
| 10 | Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2015, 122, 809-816.                              | 2.5  | 186       |
| 11 | Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016, 123, 865-875.   | 2.5  | 181       |
| 12 | Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2017, 124, 464-478.                                                | 2.5  | 164       |
| 13 | Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2017, 124, 97-104.      | 2.5  | 158       |
| 14 | Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2019, 126, 252-260.         | 2.5  | 153       |
| 15 | Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, 394-409.                               | 2.5  | 153       |
| 16 | Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2015, 122, 1846-1853.e5.                  | 2.5  | 144       |
| 17 | Retinopathy and Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>JAMA Ophthalmology</i> , 2012, 130, 1136.                                   | 2.6  | 117       |
| 18 | Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality. <i>Hypertension</i> , 2018, 71, 1101-1107.                                          | 1.3  | 99        |

| #  | ARTICLE                                                                                                                                                                                                                    | IF  | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). <i>Ophthalmology</i> , 2016, 123, 609-616.                                         | 2.5 | 93        |
| 20 | Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016, 123, 1530-1540.                   | 2.5 | 92        |
| 21 | Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>JAMA Ophthalmology</i> , 2014, 132, 915.                                                                          | 1.4 | 87        |
| 22 | Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). <i>Ophthalmology</i> , 2015, 122, 2523-2531.e1.                           | 2.5 | 84        |
| 23 | Incidence of Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2013, 120, 2035-2041.                                          | 2.5 | 81        |
| 24 | Prevalence of Ocular Fundus Pathology in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 867-873.                                                    | 2.2 | 65        |
| 25 | Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: The CRIC study. <i>Atherosclerosis</i> , 2018, 271, 53-60.                                                          | 0.4 | 63        |
| 26 | Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2018, 125, 1037-1046.                                                                      | 2.5 | 60        |
| 27 | Effect of sildenafil citrate (Viagra) on retinal blood vessel diameter. <i>American Journal of Ophthalmology</i> , 2002, 133, 809-812.                                                                                     | 1.7 | 59        |
| 28 | Effects of dorzolamide hydrochloride 2% on the retinal circulation. <i>Acta Ophthalmologica</i> , 2009, 75, 236-238.                                                                                                       | 0.4 | 54        |
| 29 | Photographic Assessment of Baseline Fundus Morphologic Features in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2012, 119, 1634-1641.                                      | 2.5 | 53        |
| 30 | Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2015, 122, 1203-1211.                                       | 2.5 | 48        |
| 31 | Outcomes of Eyes with Lesions Composed of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). <i>Ophthalmology</i> , 2015, 122, 391-398.e5.                                         | 2.5 | 46        |
| 32 | Association Between Retinopathy and Cardiovascular Disease in Patients With Chronic Kidney Disease (from the Chronic Renal Insufficiency Cohort [CRIC] Study). <i>American Journal of Cardiology</i> , 2012, 110, 246-253. | 0.7 | 45        |
| 33 | Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials. <i>Ophthalmology Retina</i> , 2018, 2, 525-530.                                                                        | 1.2 | 42        |
| 34 | Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016, 123, 352-360.           | 2.5 | 37        |
| 35 | Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, S135-S145.                                                                                    | 2.5 | 36        |
| 36 | Retinopathy and CKD as Predictors of All-Cause and Cardiovascular Mortality: National Health and Nutrition Examination Survey (NHANES) 1988-1994. <i>American Journal of Kidney Diseases</i> , 2014, 64, 198-203.          | 2.1 | 30        |

| #  | ARTICLE                                                                                                                                                                                                                | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Association Between Progression of Retinopathy and Concurrent Progression of Kidney Disease. JAMA Ophthalmology, 2019, 137, 767.                                                                                       | 1.4 | 28        |
| 38 | Retinopathy and Progression of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1217-1224.                                                                                                 | 2.2 | 25        |
| 39 | Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2019, 126, 743-751.                                                                   | 2.5 | 20        |
| 40 | Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen. JAMA Ophthalmology, 2018, 136, 682.                                                                              | 1.4 | 17        |
| 41 | Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT. Ophthalmology Retina, 2019, 3, 316-325.                                         | 1.2 | 17        |
| 42 | Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmology, 2016, 134, 674.    | 1.4 | 16        |
| 43 | Retinopathy and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease (from the) Tj ETQq1 1 0.784314 rgBT /Over<br>0.7 15                                                                         | 0.7 | 15        |
| 44 | Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy. Ophthalmology Retina, 2020, 4, 889-898.                                                                                                   | 1.2 | 15        |
| 45 | Effect of oral felodipine on ocular circulation. International Ophthalmology, 1999, 23, 79-84.                                                                                                                         | 0.6 | 12        |
| 46 | Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2016, 123, 858-864.                                                            | 2.5 | 12        |
| 47 | Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial. JAMA Ophthalmology, 2020, 138, 510.                                  | 1.4 | 12        |
| 48 | Visual and Morphologic Outcomes in Eyes with Hard Exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology Retina, 2017, 1, 25-33.                                               | 1.2 | 10        |
| 49 | Linking OCT, Angiographic, and Photographic Lesion Components in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2018, 2, 481-493.                                                                 | 1.2 | 10        |
| 50 | Short-term effects of topical levobunolol on the human retinal circulation. Eye, 1997, 11, 371-376.                                                                                                                    | 1.1 | 9         |
| 51 | Delayed Patchy Choroidal Filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). American Journal of Ophthalmology, 2014, 158, 525-531.e2.                                             | 1.7 | 9         |
| 52 | Progression of retinopathy and incidence of cardiovascular disease: findings from the Chronic Renal Insufficiency Cohort Study. British Journal of Ophthalmology, 2021, 105, 246-252.                                  | 2.1 | 9         |
| 53 | Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials. American Journal of Ophthalmology, 2021, 223, 338-347. | 1.7 | 9         |
| 54 | Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology Retina, 2021, 5, 962-974.                                                             | 1.2 | 9         |

| #  | ARTICLE                                                                                                                                                                                                                  | IF  | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Author reply. <i>Ophthalmology</i> , 2014, 121, e35.                                                                                                                                                                     | 2.5 | 7         |
| 56 | Effect of one week of levobunolol HCl 0.5% on the human retinal circulation. <i>Current Eye Research</i> , 1997, 16, 191-196.                                                                                            | 0.7 | 6         |
| 57 | Association between pseudodrusen and delayed patchy choroidal filling in the comparison of age-related macular degeneration treatments trials. <i>Acta Ophthalmologica</i> , 2017, 95, e518-e520.                        | 0.6 | 6         |
| 58 | Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2019, 137, 1306.                                                                                    | 1.4 | 6         |
| 59 | SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. <i>Retina</i> , 2021, 41, 1455-1462.                                 | 1.0 | 6         |
| 60 | Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5. <i>JAMA Ophthalmology</i> , 2020, 138, 276. | 1.4 | 5         |
| 61 | Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology Retina</i> , 2022, 6, 771-785.                                                     | 1.2 | 5         |
| 62 | ASSOCIATION BETWEEN ORAL IRON SUPPLEMENTATION AND RETINAL OR SUBRETINAL HEMORRHAGE IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. <i>Retina</i> , 2019, 39, 1965-1972.                          | 1.0 | 2         |
| 63 | BETA-PERIPAPILLARY ATROPHY AND GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. <i>Retina</i> , 2021, 41, 125-134.                                                            | 1.0 | 1         |
| 64 | Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials. <i>British Journal of Ophthalmology</i> , 2023, 107, 1000-1006.                                         | 2.1 | 0         |